Generex Biotechnology has completed enrollment of the AE37 breast cancer immunotherapy trial for subsidiary Antigen Express. The Phase II trial is designed to assess the ability of AE37 to reduce the risk of relapse in patients who have had breast cancer. While a pre-planned primary efficacy analysis is underway, completion of enrollment sets the time-point for the end-of-trial analysis, scheduled to be conducted one year’s time. The trial has enrolled more than 300 patients at 15 sites i...